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Abstract
Background: Long-term benefits of combination antiretroviral therapy (cART) initiation during primary HIV-1 infection are
debated.
Methods: The evolution of plasma HIV-RNA (432 measurements) and cell-associated HIV-DNA (325 measurements) after
cessation of cART (median exposure 18 months) was described for 33 participants from the Zurich Primary HIV Infection
Study using linear regression and compared with 545 measurements from 79 untreated controls with clinically diagnosed
primary HIV infection, respectively a known date for seroconversion.
Results: On average, early treated individuals were followed for 37 months (median) after cART cessation; controls had 34
months of pre-cART follow-up. HIV-RNA levels one year after cART interruption were 20.8 log10 copies/mL [95% confidence
interval 21.2;20.4] lower in early treated patients compared with controls, but this difference was no longer statistically
significant by year three of follow-up (20.3 [20.9; 0.3]). Mean HIV-DNA levels rebounded from 2 log10 copies [1.8; 2.3] on
cART to a stable plateau of 2.7 log10 copies [2.5; 3.0] attained 1 year after therapy stop, which was not significantly different
from cross-sectional measurements of 9 untreated members of the control group (2.8 log10 copies [2.5; 3.1]).
Conclusions: The rebound dynamics of viral markers after therapy cessation suggest that early cART may indeed limit
reservoir size of latently infected cells, but that much of the initial benefits are only transient. Owing to the non-randomized
study design the observed treatment effects must be interpreted with caution.
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Introduction
The benefits of early initiation of combination antiretroviral
treatment (cART) during primary HIV-1 infection (PHI) (hence-
forth ‘‘early cART’’) are controversial, because results from
previous studies do not seem to be consistent [1,2,3,4]. While
some authors reported clinical benefits of early cART in terms of
higher CD4 cell counts relative to controls [5,6], these findings
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could not be confirmed by others [7,8,9]. Also, discrepant reports
exist on the impact of early cART on post-treatment viral
setpoints, with some studies corroborating [5,6,10,11,12,13] and
others rejecting the hypothesis of a possible sustained decrease in
viral setpoint following treatment with cART during PHI
[14,15,16,17,18]. These studies are difficult to compare however,
and there are multiple explanations for the discrepancies, which
include differences in timing of cART initiation, type and duration
of initial cART, as well as in the choice of controls and the length
of follow up [19]. Emerging randomized clinical trials also point
toward a beneficial effect of early therapy during acute infection
[20,21].
Moreover, while short to intermediate impacts of early therapy
on viral markers are relatively well studied, there are comparably
few data on the long term evolution of HIV-RNA and HIV-DNA
after cessation of early cART [5,14]. Previously we have reported
differences in HIV-RNA and HIV-DNA setpoints measured after
cessation of initial cART between patients diagnosed with PHI
who have either started therapy within 60 days of infection (early
starters) or after 60 days (later starters) [22]. This analysis included
HIV-RNA values measured up to one year after therapy cessation.
Here, we aim to describe the long-term dynamics and the
correlation of HIV-RNA and -DNA markers before, during and
after treatment started at time of PHI.
Methods
Ethical Statement
The Zurich Primary HIV Infection Study (ZPHI) has obtained
written informed consents from their patients, and the study
protocol was approved by the ethics committee of the University
Hospital of Zurich. The Swiss HIV Cohort Study (SHCS) has
obtained written informed consent from its participants and has
been approved by ethical committees of all participating
institutions, which are the Kantonale Ethikkommission (KEK)
Bern, Bern; the Ethikkommission beider Basel (EKBB), Basel; the
comite´ d’e´thique du de´partement de me´decine, Hoˆpitaux
Universitaires de Gene`ve, Geneva; the commission d’e´thique de
la recherche clinique, Faculte´ de Biologie et de Me´decine,
Universite´ the Lausanne, Lausanne; the Comitato etico canto-
nale, Republica e Cantone Ticino, Bellinzona; the Ethikkommis-
sion des Kantons St. Gallen, St. Gallen; and the Kantonale
Ethikkommission (KEK), Gesundheitsdirektion Kanton Zu¨rich,
Zurich.
Patients
Patients presenting with acute or recent HIV-1 infection were
enrolled in the Zurich Primary HIV Study (www.clinicaltrials.gov,
NCD00537966) [23,24] between November 2002 and July 2007.
This study is described in details elsewhere [22,24]. In brief,
acutely and recently HIV-1 infected individuals are offered
standard first line cART [25], and after one year of viral
suppression below detection limits they can elect to stop therapy.
Further inclusion criteria for this analysis are outlined in Figure 1.
The control group of untreated, chronically infected patients was
selected from the Swiss HIV Cohort Study (described in [26]) and
consisted of patients with a positive HIV test, clinically diagnosed
primary HIV infection and at least 2 HIV-RNA measurements 90
days after the first positive HIV test (to ensure that these patients
were no longer in the acute phase). Of those, approximately 41%
also had negative and positive HIV-tests performed within 180
days available. A full description of the estimation procedures for
the infection date of early treated individuals is given in [22].
For the untreated controls, the infection was assumed to have
occurred 30 days prior to the diagnosis of the primary HIV
infection.
Although formally two independent studies, all ZPHI partici-
pants included in this analysis were also enrolled in the SHCS,
and clinical data and laboratory measurements are exchanged
anonymously between studies. The ZPHI exclusively recruits
participants from the Zurich region, and controls were selected
from the remaining SHCS study centers, where early antiretroviral
therapy during primary HIV infection was not standard of care at
time of study enrolment. Our study design therefore resembles that
of a multi-centric study, in which one center exclusively receives
the intervention and all other centers recruit controls. Noteworthy,
the SHCS is highly representative for the HIV-1 epidemic
in Switzerland and encompasses approximately 50% of all HIV-
infected, 75% of all individuals receiving antiretroviral therapy,
and 75% of all individuals with a CDC stage C diagnosis [27].
The methods for collection of HIV-DNA data are described
elsewhere [22,28,29]. HIV-RNA in plasma was measured using
Amplicor HIV-Monitor version 1.5 (Roche Diagnostics, Basel,
Switzerland).
Statistical methods
Pre-treatment dynamics of HIV-RNA and -DNA were
evaluated with linear regression models including linear and
quadratic terms (to account for possible non-linear dynamics).
Patients only contributed one data point per analysis. The final
model was selected based on the basis of adjusted R2 values.
The on-treatment dynamics of HIV-RNA was only analyzed
descriptively, because it has been extensively studied before [30]
and the HIV-RNA assay detection limit of 50 copies/mL
precludes sensible modeling analyses of long term decays on
therapy. Decay rates of HIV-DNA during treatment were
modeled as a two phase decay according to the following
equation: V(t)~P1e
-d1tzP2e
-d2t, where d1 and d2 are the first-
and second-phase decay rates and P1 and P2 are intercepts. To
account for the fact that patients contributed several measure-
ments to the analysis we used a non-linear mixed model with
random slope and random intercept.
Longitudinal analyses of the evolution of HIV-RNA and -DNA
markers after therapy cessation included several measurements per
patient and were therefore performed by using linear mixed models
with random slope and random intercept. All measurements taken
between 30 days after cART stop and 18 months (corresponding to
the median follow-up time for HIV-DNA measurements) were used
in this analysis. Time since therapy cessation was modeled linearly,
with different linear slopes for early starters and untreated controls,
or as restricted cubic splines with three knots. The final model was
selected by comparison of the Akaike information criterion.
In addition, long term evolution of off-therapy HIV-RNA
measurements were compared between patients with early cART
initiation and untreated control patients from the SHCS. All
measurements taken 30 days after therapy cessation until therapy
resumption (early starters) or 90 days after the first positive HIV test
until therapy initiation (control group) were considered in the
analysis. Data were analyzed with linear mixed models including time
as a restricted cubic spline with three knots. Because the magnitude of
HIV-RNA is linked with the speed at which patients will start therapy
through CD4 cell decline [31], this can introduce a bias into the
analysis [19]. For example, individuals with high viral setpoints may
have a steeper CD4 decline and may tend to resume therapy earlier,
thus lowering the average population viral setpoint.We dealt with this
problem by artificially censoring our analysis after 36 months of
follow-up, which corresponds to the median post-treatment follow-up
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time, and, in addition, by using joint mixed models on the full data
set, which adjusts longitudinal analyses of viral markers for factors
that are associated with the time until therapy is resumed or initiated,
such as CD4 cell counts [32].
Statistical analyses were performed using R 2.10 (www.r-
project.org) with the NLME library (version 3.1–89) and the JM
package (version 0.6.1) [32], and Stata 11.1/SE (Stata Corp.
College Station, TX). All analyses were performed on log10
transformed data. Model assumptions were checked by plotting
fitted values versus residuals and residuals against time. The level
of significance was set at p,0.05, and all p-values were two-sided.
Results
Patient population
HIV-DNA was measured from 67 patients who started cART
within the first four months of their HIV infection. Of these, 59 were
finally included in the HIV-DNA decay study and 33 in the cART
interruption analysis, respectively (Figure 1). In the full data set of 67
patients the majority of individuals were males who had acquired
HIV through homosexual contacts and were infected with HIV
subtype B (n= 44, 66%). A further subgroup of notable size (n= 14,
21%) consisted of individuals with heterosexual mode of HIV
acquisition and infection with HIV subtypes other than B
(predominantly CRF_01, n= 8). All patients initiated cART with
protease inhibitors (65 lopinavir, 2 unboosted nelfinavir) and two
nucleoside reverse transcriptase inhibitors. Median [interquartile
range] baseline CD4 counts and HIV-RNA measurements were
454 cells/mL [407; 500] and 5.3 log10 copies/mL [5.1; 5.5],
respectively. Median time from infection to the first laboratory
measurements (CD4, HIV-RNA, HIV-DNA) and cART initiation
was 1.6 months [1.4; 1.8]. The median treatment duration for those
individuals who stopped therapy was 18.2 months [15.6; 20.5].
Dynamics of HIV-DNA and HIV-RNA before early cART
initiation
As illustrated by Figure 2A, the majority of baseline measure-
ments for the 67 patients were taken early after infection at a time
Figure 1. The algorithm used to determine the inclusion (in boxes with continuous bounds) and exclusion (in boxes with
interrupted bounds) in pre-defined sub-analyses to explore the effect of early started antiretroviral therapy in primary HIV-
infected individuals.
doi:10.1371/journal.pone.0027463.g001
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when HIV viral loads are typically very high in most patients. This
dynamic appeared to be non-linear in the case of HIV-RNA,
because a regression with a linear slope and a non-linear
component (i.e. the square of time since infection) showed a
better fit to the data (R2= 0.25, F-test p,0.001) than a model with
a linear component only (R2 = 0.16, F-test p,0.001). In contrast,
the decrease of log10 HIV-DNA over time was better described by
a simple regression with a linear decay (R2 = 0.02, F-test p,0.13
vs. R2 = 0.01, F-test p,0.26 when including a non-linear
component, Figure 2B). Despite the distinct dynamics of HIV-
RNA and HIV-DNA, we observed a moderate correlation
between these two markers, as shown in Figure 2, panel C.
Dynamics of HIV-DNA and HIV-RNA on therapy
The dynamics of HIV-DNA and -RNA on therapy was
evaluated for the 59 patients with successful cART for at least
180 days. As expected, HIV-RNA dropped rapidly to undetect-
able levels during treatment (Figure 2D). In contrast, the decay of
HIV-DNA occurred much slower. The non-linear modeling
analysis shows a two-phase exponential decay (Figure 2E), which
had a better model fit than simple one phase decay models. This
analysis indicated a fast initial decay of HIV-DNA of 1.22 log10
[95% confidence interval 1.04; 1.40] with a half-life of 116 days
[93; 153]. The second phase decay was much slower, and decay
rates were no longer significantly different from zero (NLMM:
2561025 [2261024; 661025]). Thus, HIV-DNA levels re-
mained stable around 2.04 logs10 DNA [1.81; 2.27] after
approximately 12 months of therapy (Figure 2E).
Interestingly, one individual had several consecutive undetect-
able HIV-DNA levels during therapy. This male person acquired
HIV through heterosexual contacts, was infected with subtype
CRF01_AE and had very low baseline HIV-DNA (18 copies/106
Figure 2. Time courses of and correlations between HIV-DNA and HIV-RNA measurements. Figure 2 depicts time courses of and
correlations between HIV-DNA and HIV-RNA measurements obtained before (panels A, B, C), during (panels D, E) and after early antiretroviral therapy
initiation (panels F, G, H) in primary HIV-infected individuals. Panels A, B and C show the time dependency of pre-treatment HIV-DNA and -RNA
measurements (n = 67 patients). The curves show fits from linear regression including linear and quadratic terms. Final model selection was based on
adjusted R2 values. Panel A plots plasma HIV-RNA (log10 copies/mL) against time since infection, panel B shows Cell associated HIV-DNA (log10 copies/
million cells), and panel C displays the correlation analysis of pre-treatment HIV-RNA and HIV-DNA. Panels D and E depict the dynamics of HIV-RNA
(n = 700 measurements) and HIV-DNA (n= 737 measurements) during treatment with combination antiretroviral therapy in 59 patients. Panel D
shows longitudinal HIV-RNA measurements during treatment. Note that undetectable HIV-RNA measurements were artificially set to 0. Panel E shows
results from non-linear modeling analyses of the longitudinal course of HIV-DNA under antiretroviral therapy. Panels F and G show the evolution of
viral marker pairs (HIV-RNA and HIV-DNA; n = 203 measurements) up to 18 months after therapy cessation (n = 33 patients). Curves were fitted with
linear mixed models with random intercepts and random slopes. Panel H displays the correlation between post-therapy HIV-RNA and HIV-DNA
measurements. The correlation coefficient shown is the median of 33 individual Spearman correlation analyses for each patient.
doi:10.1371/journal.pone.0027463.g002
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cells) and HIV-RNA (609 copies/mL), measured 34 days after
HIV infection. HIV-DNA and HIV-RNA measurements became
detectable again after therapy cessation (10 copies/106 cells and
100 copies/mL, respectively). However, approximately one year
after treatment cessation this individual’s HIV-RNA reached 3000
copies/mL and attained 18000 copies/mL after two years.
Correlation of HIV-RNA and HIV-DNA up to 18 months
after cessation of antiretroviral therapy
Next we studied the rebound of HIV-RNA and -DNA after
cessation of cART and the correlation of these two viral markers.
For this analysis, all measurements taken 30 days after therapy
stop and up to 18 months later were considered. The best curve fit
for HIV-RNA was a cubic spline with knots placed at 1.2, 6.4, and
14.4 months, yielding a curve with a steep initial increase and a
relatively flat region after 9 months (Figure 2F). The best-fit curve
for HIV-DNA, based on a linear and a quadratic term, looked
very similar to the dynamics in HIV-RNA (Figure 2G). Conse-
quently, the correlation of HIV-RNA and HIV-DNA measure-
ments was quite strong in the post-therapy phase (Figure 2H).
When performing separate Spearman correlation analyses for
each patient, the median Spearman correlation coefficient over all
individuals was 0.71, which was significantly different from 0 by
the Wilcoxon signed rank test (p = 0.003).
We further aimed to find predictors for post-treatment HIV-
RNA levels. We hypothesized that the following parameters may
possibly have an impact: duration of antiretroviral therapy, timing
of therapy initiation (#60 after infection or later, as described in
[22]), and pre-treatment levels of HIV-DNA and CD4 cell counts.
Analyses were further adjusted for patient sex, age, ethnicity, and
mode of HIV-acquisition. As previously reported [22] and shown
in Table 1, the only parameter of interest showing statistical
significance in the multivariable model was timing of treatment:
individuals with antiretroviral therapy initiation #60 days after
infection (n= 24) tended to have lower post-treatment HIV-RNA
levels than patients with therapy start between 61 and 120 days
(n = 9). The appropriateness of the 60 day break point for this
analysis was further confirmed by use of fractional polynomial
regression (not shown) [33].
Long term evolution of viral markers
We also studied the long term evolution of HIV-RNA upon
cART cessation among patients with early cART initiation and
the untreated controls. Their characteristics are compared in
Table 2. Relevant differences were observed in the magnitude of
baseline CD4 with a 160 cells higher median value in the control
group and, as expected by design, in the frequency and timing of
therapy initiation. As shown in Figure 3A, HIV-RNA levels in
early cART initiators were generally below those from the control
group. Predictions from the best-fit model adjusted for age, sex,
ethnicity and mode of HIV acquisition indicate that after 1 year of
follow-up early starters on average had -0.74 log10 copies lower
HIV-RNA levels/mL ([95% confidence interval 21.17; 20.31],
p,0.001). This difference diminished over time, however, and
after 2 and 3 years was reduced to 20.42 ([20.91; 0.74],
p = 0.096) and20.25 ([2.0.94; 0.43], p= 0.468) log10 copies HIV-
RNA/mL, respectively. While, overall, there was no difference in
rates of treatment initiation (controls, median time from first
positive HIV test +90 days to therapy start: 30 months) or
resumption (early treated individuals, median time after stop of
first therapy: 37 months, log rank p= 0.64), Cox proportional
hazard regression suggested an association of CD4 count levels at
baseline, which differed between early treated individuals and
controls, with the probability for therapy initiation (Table S1).
Nevertheless an extension of follow-up time to 48 months in
combination with a joint modeling approach of HIV-RNA
evolution and time to therapy initiation yielded almost identical
results (Table S2). Additional sensitivity analyses were performed
by including all control patients (n = 79) and only early treated
individuals with a therapy start within 60 days after infection
(n= 24), which was associated with lower viral load levels up to 18
months after therapy cessation in the analysis shown in Table 1, or
by restricting the control population to individuals who, in
addition to a clinical primary HIV diagnosis, also had negative
and positive HIV tests not longer than 180 days apart (n = 32).
Neither of these sensitivity analyses altered our conclusions,
because the shapes of HIV-RNA trajectories did not change
substantially (Table S2).
The dynamics of HIV-DNA over 36 months after therapy
cessation resembled those of HIV-RNA by showing an increase in
the initial phase from approximately 2 log10 copies/10
6 cells
(Figure 3B) after treatment stop to 2.62 log10 copies/10
6 cells
[95% confidence interval 2.36; 2.88] and remaining at a stable
level of approximately 2.7 log10 copies HIV-DNA/10
6 cells
thereafter (estimate for month 24: 2.73 [2.45; 3.02]; month 36:
2.75 [2.35; 3.15]). Of note, this plateau was similar to the average
of 9 randomly selected measurements of HIV-DNA from the
untreated control group (2.8 log10 copies HIV-DNA, [2.48; 3.11],
indicated by dotted line in Figure 3B). The joint modeling analysis
yielded a similar longitudinal post-therapy course for HIV-DNA in
early treated individuals (not shown).
Discussion
In this analysis we studied the evolution of HIV-RNA and HIV-
DNA measurements before (n = 67), during (n = 59) and after
antiretroviral therapy (n= 33) in individuals with therapy initiation
within 4 months after HIV infection. As our assessment of HIV-
DNA measurements sampled before therapy initiation has shown,
DNA levels declined during the first few weeks after infection,
although this decrease was far less pronounced than for HIV-
RNA. Moreover, only a moderate correlation between pre-
treatment HIV-RNA and HIV-DNA was observed, which
contrasts starkly with the strong correlation of these parameters
after therapy cessation. This suggests that, at the time of pre-
treatment data collection, the steady state of virus production and
decay was not yet established. Our observation that pre-treatment
HIV-DNA values were not predictive for post-treatment HIV-
RNA levels is consistent with this hypothesis.
While HIV-RNA measurements rapidly attained undetectable
levels after treatment initiation, HIV-DNA levels were much
slower to respond and, with the exception of one patient
(Figure 3B), never reached undetectable levels. On average a level
of 2 log10 copies HIV-DNA persisted despite a median exposure to
combination therapy with boosted protease inhibitors of 18
months, and we observed no evidence that a further extension
of therapy duration may yield any benefit in terms of HIV-DNA
reduction. This is not surprising given that the PBMC associated
DNA levels we measured during the treatment phase largely
reflect proviral DNA that is integrated into the host DNA and
exhibit a very long decay half life [34,35]. On a broader view, this
finding confirms conventional wisdom that latent HIV-DNA
reservoirs cannot be purged by currently available antiretroviral
therapies even when started very early [36].
After cessation of antiretroviral therapy, there was a slow
increase in HIV-DNA, which seemed to level off after
approximately 1 year. In contrast, there was an almost
instantaneous rebound from undetectable to detectable HIV-
Viral Marker Dynamics after Early cART
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RNA and a continuous rise in levels over the first 18 months after
treatment stop. However, when including follow-up data for up
to 36 months there was also evidence for a deceleration of
increase rates for HIV-RNA levels, similar to the dynamics of
HIV-DNA. Indeed, our statistical models suggest that, three years
post therapy, individuals who had undergone early treatment
almost attained the same HIV-RNA levels as untreated controls,
whereas in the first year after treatment stop HIV-RNA levels
were still notably different between early cART starters and
untreated controls. Similar rebound dynamics of post-treatment
HIV-RNA have previously been reported by other studies
[5,14,18].
Table 1. Predictors for post-therapy HIV-RNA levels collected up to 18 months after stop of antiretroviral therapy (included 203
HIV-RNA measurements from 33 patients). Time was modeled as a restricted cubic spline with three knots (coefficients not shown).
Univariable P-value Multivariable P-value
regression coefficient regression coefficient
[95% CI] [95% CI]
Male sex 0.29 [20.99 to 1.57] 0.656 20.90 [22.27 to 0.48] 0.202
White ethnicity (vs. non-white) 20.79 [22.59 to 1.00] 0.386 20.25 [21.86 to 1.37] 0.766
Age (per 10 years older) 20.21 [20.67 to 0.26] 0.381 0.41 [20.11 to 0.94] 0.124
Acquired HIV through homosexual contacts (vs.
heterosexual contacts)
0.94 [0.12 to 1.76] 0.025 1.37 [0.32 to 2.42] 0.01
CD4 cell count before therapy start (per 10 cells higher) 20.02 [20.04 to 0.01] 0.163 20.02 [20.04 to 0.01] 0.137
Log10 HIV-DNA before therapy start 0.45 [20.24 to 1.14] 0.204
Duration of initial treatment with combination
antiretroviral therapy (per month longer)
0.02 [20.05 to 0.08] 0.614
Treatment initiation ,60 days after HIV infection (vs. later) 20.84 [21.78 to 0.11] 0.082 21.01 [21.98 to 20.04] 0.041
doi:10.1371/journal.pone.0027463.t001
Table 2. Comparison of baseline characteristics for early treated individuals (n = 33) and untreated controls with a clinical
diagnosis of primary HIV infection (n = 79).
Early treated individuals Controls P-value
N 33 (100.0) 79 (100.0)
Age 39 [36;42] 37 [35;39] 0.311
Baseline CD4 count 499 [436; 561] 661 [606; 717] ,0.001
Baseline HIV-RNA 4.9 [4.5; 5.2] 4.9 [4.6; 5.1] 0.990
Ethnicity 0.704
Black 0 (0.0) 1 (1.3)
Other 2 (6.1) 2 (2.5)
White 31 (93.9) 76 (96.2)
Year of HIV-1 Infection 2004 [2003; 2004] 2005 [2004; 2005] 0.044
Clinical diagnosis of primary HIV infection 32 (97.0) 79 (100.0) 0.295
Mode of HIV-1 acquisition 0.327
Heterosexual 10 (30.3) 22 (27.8)
Homosexual 22 (66.7) 47 (59.5)
Other 1 (3.0) 10 (12.7)
Male sex 29 (87.9) 66 (83.5) 0.774
HIV Subtype ,0.001
CRF 01_AE 8 (24.2) 1 (1.3)
CRF 02_AG 0 (0.0) 5 (6.3)
B 22 (66.7) 55 (69.6)
Other 3 (9.1) 18 (22.8)
Time from infection to baseline (months) 20 [17;23] 6 [5;8] ,0.001
Ever started antiretroviral therapy 33 (100) 51 (64.6) ,0.001
Time to therapy initiation (months) 1.7 [1.5; 1.9] 40.5 [34.3; 46.6] ,0.001
The baseline for this analysis was set at 30 days after therapy cessation for the intervention group and at 90 days after the first positive HIV test for the control group.
doi:10.1371/journal.pone.0027463.t002
Viral Marker Dynamics after Early cART
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The present study offers possible explanations for the differing
impact assessments of early therapy on post-treatment viral loads.
As indicated by our 18 month analysis (Table 1 and [22]) and data
from other studies [6,11] the timing of treatment initiation may be
of importance, with very early treatment initiation generally
yielding better outcomes in terms of lower HIV-RNA levels.
Furthermore, discrepant results may have arisen from differences
in post-therapy follow-up time for outcome assessment, with
shorter analysis time frames between 24 and 48 weeks after
therapy cessation more likely pointing towards a benefit of early
therapy [12,22,37], and studies following the HIV-RNA trajecto-
ries after therapy stop generally finding decreasing differences in
viral loads between early treated individuals and controls
[5,6,15,18]. The present analysis adds to these longitudinal
observations by specifically addressing statistical problems of
non-random censoring of follow-up, meaning that patients with
faster HIV-1 progression and potentially higher HIV-RNA loads
initiate therapy earlier, and confounding by severity of primary
HIV-1 infection symptoms [19,37].
Some limitations of this study should be noted, most
importantly that our analysis is observational and therefore
treatment strategies were not subject to randomization. Our
findings must therefore be interpreted with caution. Systematic
differences between the group of early treated individuals and
untreated controls may have affected our analysis, such as the
severity of the acute retroviral syndrome, which has been
correlated with the magnitude of setpoint viral load. If heavily
symptomatic primary infected individuals were more likely to
receive early therapy, this could possibly increase the group
average of post-therapy viral loads of early treated individuals,
therefore diminishing the true treatment effect. A second
limitation concerns differences regarding the time axes for early
treated individuals and controls. By design, the early treated
individuals will have been infected for a longer period of time (20
months) than controls (6 months) in the treatment effects analysis,
because early starters will in minimum have received 6 months of
therapy, whereas the baseline in untreated controls was set at 90
days after the first positive HIV test. While this systematic
difference could have confounded our analysis, for instance via a
time dependency of immune response or co-receptor switch, a
large effect on the observed treatment effects seems implausible.
Additionally, diagnoses of primary HIV infections are not based
on a standardized protocol within the SHCS, and thus infection
date estimates from untreated controls are less precise than those
from early treated individuals. Restricting this imprecision to 3
months by only including controls with negative and positive HIV
tests within 6 months (n = 32) in a sensitivity analysis had little
impact on our estimates of treatment effects, however (Table S2).
Taken together, these data suggest that the initiation of
antiretroviral therapy during PHI may lead to reductions of post-
therapy HIV-RNA and HIV-DNA levels, but further demonstrate
that these initial benefits may be waning over time. The major
mechanism behind our finding is most likely the limited size of the
long-lived latent reservoir [38,39,40] by an abrogated establishment
of this reservoir by early cART, as has been shown by viral
outgrowth assays [26], by profound depletion of transcriptionally
active cells [29] and by reduced amounts of proviral DNA in PBMC
[22]. The post-treatment dynamics of viral markers uncovered in
the current analysis are indeed suggestive for such an effect of early
therapy. However, these analyses also show that the establishment
of reservoirs is merely postponed: After approximately 12 and 36
months, HIV-DNA and HIV-RNA levels resembled those from
untreated chronic control patients. Given the transient nature of
effects on viral markers, the current lack of ways to exploit these
reductions in HIV-RNA and HIV-DNA for patient benefit, and
against the background of recent findings of detrimental effects of
viral replication on morbidity and mortality [41,42] these data
suggest that therapy resumption in early treated individuals should
not be deferred for too long [25].
Supporting Information
Table S1 Factors associated with treatment resumption
(early treated individuals, n= 33) or treatment initiation
(controls, n= 79) in univariable and multivariable Cox
regression models.
(DOC)
Table S2 Estimates of HIV-RNA levels at 12, 24, and 36
months after baseline from linear mixed models and
joint models. Estimates of difference in HIV-RNA between
early starters and controls that printed in bold face are statistically
significant at the 5% level.
(DOC)
Figure 3. Long-term evolution of viral markers. Panel A displays the evolution of HIV-RNA measurements up to 36 months after therapy
cessation in 33 individuals with therapy initiation during PHI (n = 432 measurements, light grey symbols) and 79 chronically infected participants of
the Swiss HIV Cohort Study (n = 545 measurements, dark symbols). Panel B shows longitudinal HIV-DNA measured in early starters (n = 325
measurements). Note that the dotted line represents the average of 9 randomly selected cross-sectional measurements from control patients.
doi:10.1371/journal.pone.0027463.g003
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